Get the latest news, insights, and market updates on TMDX (TransMedics Group, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of its Investigational Device Exemption (IDE) for the Next-Generation OCS ENHANCE Heart trial. This follows full FDA approval of the company's Next-Generation OCS DENOVO Lung IDE trial in January 2026 and conditional I Feb 9, 2026 - $TMDX
TransMedics Group, Inc. (TMDX): A Bull Case Theory
We came across a bullish thesis on TransMedics Group, Inc. on Johnny’s bearish Investing’s Substack. In this article, we will summarize the bulls’ thesis on TMDX. TransMedics Group, Inc.’s share was trading at $138.97 as of January 28th. TMDX’s trailing and forward P/E were 55.51 and 58.82 respectively according to Yahoo Finance. TransMedics Group (TMDX) is a U.S.-based […] Feb 4, 2026 - $TMDX
Assessing TransMedics Group (TMDX) Valuation After Strong Recent Share Price Momentum
Why TransMedics Group (TMDX) is on investors’ radar today TransMedics Group (TMDX) has been drawing attention after a period of strong share price moves, with returns of 14.6% over the past month and 3.8% over the past 3 months. See our latest analysis for TransMedics Group. The recent 1-month share price return of 14.6% at a last close of $140.99 builds on a year-to-date share price return of 14.9%, while the 1-year total shareholder return of 115.2% points to strong longer term momentum. If... Jan 29, 2026 - $TMDX
Is It Too Late To Consider TransMedics Group (TMDX) After Its 106% One Year Rally?
If you are wondering whether TransMedics Group's current share price lines up with its underlying worth, this article will walk you through what the numbers actually say about value. The stock last closed at US$138.49, with returns of 11.5% over the past month, 12.9% year to date, 106.6% over the past year, around 120% over three years, and a very large gain over five years. These figures can influence how investors think about both potential and risk. Recent coverage has focused on... Jan 28, 2026 - $TMDX
TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a global leader in organ transplant technologies and services, today announced the signing of a long-term lease for its new global headquarters at Assembly Innovation Park in Somerville, as well as the acquisition of the adjacent land parcel to create an integrated TransMedics campus environment. This strategic expansion reflects the company's commitment to accelerating the next wave of transplant innovations, growth, and the transformation Jan 12, 2026 - $TMDX
BioMed Realty and TransMedics Announce 498,000-Square-Foot Lease at Assembly Innovation Park
SAN DIEGO & SOMERVILLE, Mass., January 12, 2026--BioMed Realty, the largest privately-owned operator of real estate for the life science and technology industries, and TransMedics Group, Inc. ("TransMedics", ticker: TMDX), a publicly traded medical technology company transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that TransMedics has entered into a full building, 498,000-square-foot lease at Assembly Innovation Park, a premier life sci Jan 12, 2026 - $TMDX
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 12, 2026, at 3:00 pm Pacific Standard Time / 6:00 pm Eastern Standard Time. Dec 30, 2025 - $TMDX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple